ບາດກ້າວໃໝ່ກ່ຽວກັບການກວດເລືອດກວດຫາມະເຮັງຕ່ອມລູກໝາກໃນຂັ້ນຕົ້ນ

Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Device Designation’ for its blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company’s early-stage breast cancer detection test…